

AD _____

GRANT NUMBER DAMD17-96-1-6209

TITLE: The RIZ Gene in Human Breast Cancer

PRINCIPAL INVESTIGATOR: Shi Huang, Ph.D.

CONTRACTING ORGANIZATION: The Burnham Institute
La Jolla, CA 92037

REPORT DATE: September 1997

TYPE OF REPORT: Annual

PREPARED FOR: Commander
U.S. Army Medical Research and Materiel Command
Fort Detrick, Frederick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

DTIC QUALITY INSPECTED 2

19980310 065

REPORT DOCUMENTATION PAGE

Form Approved

OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE September 1997	3. REPORT TYPE AND DATES COVERED Annual (1 Sep 96 - 31 Aug 97)	
4. TITLE AND SUBTITLE The RIZ Gene in Human Breast Cancer			5. FUNDING NUMBERS DAMD17-96-1-6209	
6. AUTHOR(S) Shi Huang, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) The Burnham Institute La Jolla, CA 92037			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) Commander U.S. Army Medical Research and Materiel Command Fort Detrick, Frederick, Maryland 21702-5012			10. SPONSORING/MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200) The <i>RIZ</i> gene was isolated based on binding to the retinoblastoma tumor suppressor protein. <i>RIZ</i> gene normally produces two protein products, <i>RIZ1</i> and <i>RIZ2</i> , that differ in length by the presence or absence of a conserved protein motif, the PR domain, found in a subfamily of Krüppel-like zinc finger genes. <i>RIZ2</i> lacks the PR domain. <i>RIZ</i> gene maps to human chromosome band 1p36, a region that is commonly deleted or altered in a variety of human cancers including those of breast, neurocrest, colon, and liver tissues. <i>RIZ1</i> and <i>RIZ2</i> are widely expressed in normal tissues. However, <i>RIZ1</i> was undetectable in 4 of 5 breast carcinoma specimens and in 4 of 10 breast cancer cell lines. Loss of <i>RIZ1</i> expression was also commonly found in hepatoma tissues and cell lines. In contrast to <i>RIZ1</i> , <i>RIZ2</i> expression appeared normal in all cases examined. These observations suggest that loss of <i>RIZ1</i> may be involved in tumor formation; <i>RIZ1</i> but not <i>RIZ2</i> may be an inhibitor of tumor cell growth. These findings are intriguingly similar to those described for the <i>RIZ</i> -related PR gene <i>MDS1-EVI1</i> that also produces a PR domain lacking product <i>EVI1</i> . <i>EVI1</i> but not <i>MDS1-EVI1</i> acts as an oncogene.				
14. SUBJECT TERMS Breast Cancer Tumour Suppressor			15. NUMBER OF PAGES 16	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

 x Where copyrighted material is quoted, permission has been obtained to use such material.

 x Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

 x Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

 x In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

 x For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

 In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

 In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

 In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.


PI - Signature

9.29.97
Date

TABLE OF CONTENTS
ANNUAL REPORT FOR GRANT NUMBER
DAMD17-96-1-6209

FRONT COVER	Page 1
REPORT DOCUMENTATION PAGE	Page 2
FOREWORD	Page 3
TABLE OF CONTENTS	Page 4
INTRODUCTION	Pages 5-6
BODY	Pages 6-10
CONCLUSIONS	Pages 10-11
REFERENCES	Pages 12-16
APPENDICES	N/A

Loss of RIZ1 expression in human breast cancer, Annual Report 1997, PI.
Shi Huang

Introduction:

From early work on cell hybrids and on the genetics of retinoblastoma, it is now well established that loss of tumor suppressor function can lead to cancer (Knudson, 1993). There are presently more than a dozen tumor suppressor genes known, and the p53 gene and the retinoblastoma susceptibility gene (Rb) represent the two best characterized such genes (Levine, 1997; Weinberg, 1995). The RIZ1 protein is a product of the *RIZ* gene isolated in a functional screening for Rb-binding proteins (Buyse et al., 1995), and independently as a *GATA-3*-binding protein *G3B* (Shapiro et al., 1995) and as a DNA-binding protein *MTB-Zf* (Muraosa et al., 1996). *RIZ* contains an E1A like Rb-binding motif and shares an antigenic epitope with E1A. Despite this, *RIZ* gene products appear not to interact with Rb family proteins p107 and p130 (Buyse and Huang, 1997). The physiological role of the RIZ-Rb interaction is as yet undefined. RIZ1 protein has eight Kruppel-like zinc finger type DNA-binding motifs and appears to function as a DNA binding transcription factor. It is located in the nucleus (Liu et al., 1997), and can bind to GC-rich Sp-1 element and represses transcription (Xie, 1997). RIZ1 also binds to the MTE element GTCATATGAC and may activate transcription through this element (Muraosa et al., 1996).

There are several other interesting motifs in RIZ proteins, including a putative GTPase and a SH3 motif. In addition, *RIZ* encodes a PR domain of ~100 amino acids which defines a sub-family of Kruppel-like zinc finger genes; the PR domain is located at the amino-termini of these proteins. The *RIZ* gene normally produces two different products, RIZ1 and RIZ2, which differ in length by the presence or absence of the PR domain (Liu et al., 1997). An internal promoter generates RIZ2 which lacks the PR domain but is otherwise identical to RIZ1. Both products are widely expressed in adult rat tissues. Other members of the PR family include the *MDS1-EVI1* leukemia gene and the *PRDI-BF1* or *BLIMP1* transcription repressor which can drive B cell maturation (Fears et al., 1996; Huang, 1994; Keller and Maniatis, 1991; Turner et al., 1994). Remarkably similar to *RIZ*, *MDS1-EVI1* also gives rise to a PR lacking product, the

EVI1 oncoprotein, through an internal promoter (Bartholomew and Ihle, 1991; Fears et al., 1996).

There is circumstantial evidence that PR genes or the PR-containing products of these genes are tumor suppressors. The PR region of *MDS1-EVI1* is often disrupted by leukemia associated chromosomal insertions and translocations, resulting in the activation of the PR deficient *EVI1* gene which is considered oncogenic (Mitani et al., 1994; Morishita et al., 1992; Morishita et al., 1988; Nucifora et al., 1994). The *BLIMP1* gene maps to a tumor suppressor locus 6q21 (Mock et al., 1996), and is a transcriptional repressor of the *c-myc* oncogene (Lin et al., 1997). The *RIZ* gene maps to band 1p36 (Buyse et al., 1996; Muraosa et al., 1996), which commonly undergoes loss of heterozygosity (LOH) in a broad spectrum of human tumors, including those of breast, liver, colon, and neurocrest tissues (Bardi et al., 1993; Dracopoli et al., 1989; Fong et al., 1992; Genuardi et al., 1989; Harnett et al., 1991; Mathew et al., 1994; Simon et al., 1991). The mouse homolog of *RIZ* maps to chromosome 4 in between the marker *D4Mit48* and *Nppa* that shares linkage homology with human chromosome 1p36 (Mock et al., 1996). LOH of this region is common in mouse lung cancers (Herzog et al., 1995).

In aim 1 of our grant proposal, we asked whether *RIZ* gene might be altered in human breast cancer. Here, we show that loss of *RIZ1* expression but not *RIZ2* is common in human breast cancer and hepatoma tissues and cell lines. The data suggests that *RIZ1* but not *RIZ2* may be a tumor suppressor.

Results:

To study whether the *RIZ* gene might play a role in human breast cancer, we examined the expression of the two alternative forms of *RIZ*, *RIZ1* and *RIZ2*, in tumor derived cell lines and tissues using a previously described RNase protection assay (Liu et al., 1997). A representative result of this analysis is shown in Figure 1A and 1B for human hepatoma cell lines and tissues and for breast cancer cell lines. *RIZ1* and *RIZ2* expression was found in normal human placenta and liver tissues (50N), and a immortalized mammary epithelial cell line 184A1N4. However, several hepatoma and breast cancer cell lines and tissues, such as HepG2, Huh2, HA22T, Hep50T, SK-BR-3,

and MB435, showed undetectable or reduced levels of RIZ1 relative to RIZ2. Loss of RIZ1 but not RIZ2 in the tumor cell lines was also confirmed by RT-PCR analysis (Figure 1C). Overall, low or absent RIZ1 was found in 8 out of 10 hepatoma cell lines, 2 of 5 lung cancer cell lines, 2 of 7 neuroblastoma cell lines, and 4 of 10 breast cancer cell lines. In contrast, RIZ2 mRNA and protein expression (not shown) was found in all tumor cell lines and tissues examined.

To further confirm loss of RIZ1 mRNA expression in tumor tissues, we performed in situ analysis of *RIZ* gene expression in breast carcinoma specimens. Fixed breast sections from 5 infiltrating carcinomas and 7 benign breast lesions (reduction mammoplasty specimens) were examined using procedures described previously (Ji et al., 1997). A PR domain anti-sense probe was used to specifically hybridize to RIZ1 mRNA. Because RIZ2 mRNA does not contain unique sequences not present in RIZ1, a fragment of coding exon 7 was used to detect both RIZ1 and RIZ2 transcripts. Positive RIZ1 hybridization was found in normal epithelial cells in 6 of 7 normal breast tissues or benign lesions. RIZ1 was not found in stromal cells. No RIZ1 expression was found in the neoplastic epithelial cells in 4 of 5 infiltrating breast carcinomas. Representative positive staining of RIZ1 in normal ductal breast epithelial cells and in normal lobular cells is shown in Figure 1D-a and 1D-b respectively. Representative negative staining of RIZ1 in two carcinoma samples is shown in Figure 1D-d and 1D-e (the pictures shown have been counter stained with hematoxylin to reveal cells which would otherwise be unrecognizable due to lack of any hybridization signals). Similar sections of the same fixed tumors (Figure 1D-f) or normal samples (Figure 1D-c) showed positive staining for the coding exon 7 probe, indicating RIZ2 expression in transformed breast epithelial cells as well as in stromal cells. We conclude from these studies that loss of RIZ1 expression may be a common change associated with human breast cancer.

We have proposed to study monoallelic expression of RIZ gene. However, analysis of available breast cancer cell lines did not reveal abnormal allelic expression of RIZ gene.




Figure 1. RIZ1 gene expression in breast cancer and hepatoma. (A) RNase protection analysis of hepatoma cell lines and tissues. RIZ1 antisense probe was hybridized with 30 µg of total RNA prepared from different cell lines or tissues as indicated. Lanes 1-7, probe alone, tRNA, normal human placenta, hepatoma cell line HepG2, Hep3B, Huh2, and Ha22T respectively. Lanes 8-11, hepatoma tissue Hep64T, hepatoma tissue Hep34T, normal liver 50N, and hepatoma tissue Hep50T respectively. **(B)** RNase protection analysis of breast cancer cell lines. **(C)** RT-PCR analysis of RIZ1 and RIZ2 expression in human hepatoma cell lines. Lanes 1-6 represent no RNA, Hep3B, Ha22T, HepG2, Huh1, and Huh2 hepatoma cell lines respectively. DNA kb ladder (BRL) is in lane 7. **(D)** *RIZ* gene expression in human breast tissues by in situ hybridization. For tumor sections d and e, hematoxylin counterstaining was performed for viewing cells. **(a)** Positive RIZ1 staining in normal ductal breast epithelial cells but negative staining in stromal cells. **(b)** Positive RIZ1 staining in normal lobular cells. **(d)** and **(e)** Negative RIZ1 staining in highly infiltrating carcinoma cells. **(c)** and **(f)** Positive staining for coding exon 7 in normal ductal breast epithelial cells **(c)** and in highly infiltrating carcinoma cells **(f)** as well as in stromal cells **(c and f)**.

Methods:

Human breast cancer and hepatoma cell lines were grown in Dulbecco's modified Eagle medium (DMEM) plus 10% fetal calf serum. RNA was prepared using RNA-zol according to the manufacturer's recommended procedures (Tel-Test, Inc.). 20-30 µg of total RNA was used for RNase protection analysis as described previously (Liu et al., 1997).

For RT-PCR analysis of RNA from tumor cell lines, reverse transcription was performed using M-MLV reverse transcriptase (NEB) and oligonucleotide primer RP217 located in coding exon 7 (5'-CCT CTG AGC AGT CTT CAA GAG T-3'). The first strand cDNA sample was then amplified using two different sets of primers, one set (RP168 + RP217) was specific for RIZ1 and the other (RP216 + RP217) for RIZ2+RIZ1.

RP168 primer is located within exon 4 (5'-TGG CTG CGA TAT GTG AAT TG-3').
RP216 primer is located within exon 6 (5'-CAA CTG AAG ACA AGT GAG CCA GA-3').

In situ hybridization analysis of fixed breast tissues was carried out as described previously using digoxigenin-labeled probes (Ji et al., 1997). The RIZ1 antisense probe was a 0.5 kb fragment generated by T7 transcription of the amino terminal region of RIZ1 upstream of coding exon 1. The exon 7 antisense probe was a 0.5 kb fragment corresponding to amino acids 700-866 and was generated by Sp6 transcription. Sections were incubated with mouse anti-digoxigenin antibodies (Boehringer mannheim) followed by incubation with biotin-conjugated secondary rabbit antimouse antibodies (DAKO). The calorimetric detection was performed using the Universal LSAB Kit (DAKO) according to the manufacturer's instructions.

Conclusion:

A role for RIZ1 as a candidate tumor suppressor is suggested by two previous observations: RIZ1 maps to human chromosome band 1p36 and both RIZ1-related PR domain proteins are candidate tumor suppressors, because MDS1-EVI1 is disrupted in leukemia and BLIMP1 is a transcriptional repressor of *c-myc*. We provide here further evidence that RIZ1 is a candidate breast tumor suppressor. We show that RIZ1 deficiency occurs in human breast cancer.

Our data indicate that loss of RIZ1 expression may be common in human cancers, at least for breast cancer tissues and hepatoma cell lines where 80% of samples analyzed showed undetectable expression of RIZ1. It remains to be determined whether the loss of RIZ1 is correlated with LOH of 1p36. Southern blot analysis did not show evidence of gross abnormalities of RIZ1 genomic DNA in tumor cells (not shown). Inactivating RIZ1 gene expression rather than mutating RIZ1 protein structure, therefore, appears to be the basis of loss of RIZ1 in malignant cells. In the dozens of tumor cell lines examined to date, an intact RIZ2 protein was always found. Thus, relative to what appears to be negative selection against RIZ1 expression in tumor cells, the uniform presence of RIZ2 is striking, and may indicate a positive role for RIZ2 in oncogenesis. Two alternative forms of the RIZ1-related PR domain gene MDS1-EVI1 have previously been proposed to play opposite functional roles in

transformation (Soderholm et al., 1997). The need to maintain RIZ2 expression in tumor cells may explain the lack of gross mutations in *RIZ* gene because RIZ2 shares 89% of coding region with RIZ1. Of course, mutations in the PR region of RIZ1 should not affect RIZ2. Such mutations, however, must be subtle (undetectable by Southern-blot analysis). Moreover, if such mutations exist, they are likely to be rare, at least in hepatoma cell lines and breast cancers which primarily display a loss of RIZ1 transcript.

Future work will focus on establishing the relevance of the loss of RIZ1 to carcinogenesis by analyzing RIZ1 mutant mice which we have generated recently. Preliminary analysis of a small number of animals show that these RIZ1 mutant mice develop a broad and unusual spectrum of tumors later in life. Although breast cancer and hepatoma were not found, it may reflect the limited number of animals analyzed or a species difference that has previously been found in Rb knock-out mice that do not develop retinoblastoma (Clarke et al., 1992; Jacks et al., 1992; Lee et al., 1992). We will also study the mechanisms of loss of RIZ1 expression in human breast cancer. Finally, we will study whether reintroducing RIZ1 into breast tumor cells would inhibit tumor cell growth.

In conclusion, we have identified RIZ1 as a candidate tumor suppressor. RIZ1 may be useful for diagnosis and therapy of breast cancer and hepatoma, and perhaps of other human cancers as well.

References:

Bardi, G., Pandis, N., Fenger, C., Kronborg, O., Bomme, L., and Heim, S. (1993). Deletion of 1p36 as a primary chromosomal aberration in intestinal tumorigenesis. *Cancer Res.* *53*, 1895-1898.

Bartholomew, C., and Ihle, J. N. (1991). Retroviral insertions 90 kilobases proximal to the Evi-1 myeloid transforming gene activate transcription from the normal promoter. *Mol.Cell Biol.* *11*, 1820-1828.

Buyse, I. M., and Huang, S. (1997). In Vitro Analysis of the E1A-Homologous Sequences of RIZ. *J. Virol.* *71*, 6200-6203.

Buyse, I. M., Shao, G., and Huang, S. (1995). The retinoblastoma protein binds to RIZ, a zinc finger protein that shares an epitope with the adenovirus E1A protein. *Proc. Natl. Acad. Sci. USA* *92*, 4467-4471.

Buyse, I. M., Takahashi, E., and Huang, S. (1996). Physical mapping of the retinoblastoma-interacting zinc finger gene RIZ to D1S228 on chromosome 1p36. *Genomics* *34*, 119-121.

Clarke, A. R., Maandag, E. R., van Roon, M., van der Lugt, N. M., van der Valk, M., Hooper, M. L., Berns, A., and te Riele, H. (1992). Requirement for a functional Rb-1 gene in murine development. *Nature* *359*, 328-330.

Dracopoli, N. C., Harnett, P., Bale, S. J., Stanger, B. Z., Tucker, M. A., Housman, D. E., and Kefford, R. F. (1989). Loss of alleles from the distal short arm of chromosome 1 occurs late in melanoma tumor progression. *Proc. Natl. Acad. Sci. USA* *86*, 4614-4618.

Fears, S., Mathieu, C., Zeleznik-Le, N., Huang, S., Rowley, J. D., and Nucifora, G. (1996). Intergenic splicing of *MDS1* and *EVII* occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family. *Proc. Natl. Acad. Sci. USA* 93, 1642-1647.

Fong, C. T., White, P. S., Peterson, K., Sapienza, C., Cavenee, W. K., Kern, S. E., Vogelstein, B., Cantor, A. B., Look, A. T., and Brodeur, G. M. (1992). Loss of heterozygosity for chromosomes 1 or 14 defines subsets of advanced neuroblastomas. *Cancer Res.* 52, 1780-1785.

Genuardi, M., Tsihira, H., Anderson, D. E., and Saunders, G. F. (1989). Distal deletion of chromosome 1p in ductal carcinoma of the breast. *Am. J. Hum. Genet.* 45, 73-82.

Harnett, P. R., Kearsley, J. H., Hayward, N. K., Dracopoli, N. C., and Kefferd, R. F. (1991). Loss of allelic heterozygosity on distal chromosome 1p in Merkel cell carcinoma. A marker of neural crest origins? *Cancer Genet. Cytogenet.* 54, 109-113.

Herzog, C. R., Wang, Y., and You, M. (1995). Allelic loss of distal chromosome 4 in mouse lung tumors localize a putative tumor suppressor gene to a region homologous with human chromosome 1p36. *Oncogene* 11, 1811-5.

Huang, S. (1994). Blimp-1 is the murine homolog of the human transcriptional repressor PRDI-BF1. *Cell* 78, 9.

Jacks, T., Fazeli, A., Schmitt, E. M., Bronson, R. T., Goodell, M. A., and Weinberg, R. A. (1992). Effects of an Rb mutation in the mouse. *Nature* 359, 295-300.

Ji, H., Liu, Y. E., Jia, T., Wang, M., Liu, J., Xiao, G., Joseph, B. K., Rosen, C., and Shi, Y. E. (1997). Identification of a breast cancer-specific gene, BCSG1, by direct differential cDNA sequencing. *Cancer Res.* 57, 759-64.

Keller, A. D., and Maniatis, T. (1991). Identification and characterization of a novel repressor of beta-interferon gene expression. *Genes Dev.* 5, 868-879.

Knudson, A. G. (1993). Antioncogenes and human cancer. *Proc. Natl. Acad. Sci. USA* 90, 10914-10921.

Lee, E. Y., Chang, C. Y., Hu, N., Wang, Y. C., Lai, C. C., Herrup, K., Lee, W. H., and Bradley, A. (1992). Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis. *Nature* 359, 288-294.

Levine, A. J. (1997). p53, the cellular gatekeeper for growth and division. *Cell* 88, 323-31.

Lin, Y., Wong, K.-k., and Calame, K. (1997). Repression of *c-myc* Transcription by Blimp-1, an Inducer of Terminal B Cell Differentiation. *Science* 276, 596-598.

Liu, L., Shao, G., Steele-Perkins, G., and Huang, S. (1997). The retinoblastoma interacting zinc finger gene RIZ produces a PR domain lacking product through an internal promoter. *J. Biol. Chem.* 272, 2984-2991.

Mathew, S., Murty, V. V., Bosl, G. J., and Chaganti, R. S. (1994). Loss of heterozygosity identifies multiple sites of allelic deletions on chromosome 1 in human male germ cell tumors. *Cancer Res.* 54, 6265-6269.

Mitani, K., Ogawa, S., Tanaka, T., Miyoshi, H., Kurokawa, M., Mano, H., Yazaki, Y., Ohki, M., and Hirai, H. (1994). Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia. *EMBO J.* 13, 504-510.

Mock, B. A., Coleman, M. P., and Huang, S. (1996). Riz maps to distal chromosome 4 near genes involved in tumorigenesis and nerve degeneration. *Mamm. Genome* 7, 637.

Mock, B. A., Liu, L., Le Paslier, D., and Huang, S. (1996). The B-lymphocyte maturation promoting transcription factor BLIMP1/PRDI-BF1 maps to D6S447 on human chromosome 6q21-q22.1 and the syntenic region of mouse chromosome 10. *Genomics* 37, 24-28.

Morishita, K., Parganas, E., William, C. L., Whittaker, M. H., Drabkin, H., Oval, J., Taetle, R., Valentine, M. B., and Ihle, J. N. (1992). Activation of EVI1 gene expression in human acute myelogenous leukemias by translocations spanning 300-400 kilobases on chromosome band 3q26. *Proc. Natl. Acad. Sci. USA* 89, 3937-3941.

Morishita, K., Parker, D. S., Mucenski, M. L., Jenkins, N. A., Copeland, N. G., and Ihle, J. N. (1988). Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell lines. *Cell* 54, 831-840.

Muraosa, Y., Takahashi, K., Yoshizawa, M., and Shibahara, S. (1996). cDNA cloning of a novel protein containing two zinc-finger domains that may function as a transcription factor for the human heme-oxygenase-1 gene. *Eur. J. Biochem.* 235, 471-479.

Nucifora, G., Begy, C. R., Kobayashi, H., Roulston, D., Claxton, D., Pedersen-Bjergaard, J., Parganas, E., Ihle, J. N., and Rowley, J. D. (1994). Consistent intergenic splicing and production of multiple transcripts between AML1 at 21q22 and unrelated genes at 3q26 in (3;21)(q26;q22) translocations. *Proc. Natl. Acad. Sci. USA* 91, 4004-4008.

Shapiro, V. S., Lee, P., and Winoto, A. (1995). Identification and cloning of the G3B cDNA encoding a 3' segment of a protein binding to GATA-3. *Gene* 163, 329-330.

Simon, D., Knowles, B. B., and Weith, A. (1991). Abnormalities of chromosome 1 and loss of heterozygosity on 1p in primary hepatomas. *Oncogene*. 6, 765-770.

Soderholm, J., Kobayashi, H., Mathieu, C., Rowley, J. D., and Nucifora, G. (1997). The leukemia-associated gene MDS1/EVI1 is a new type of GATA-binding transactivator. *Leukemia* 11, 352-8.

Turner, C. A., Jr., Mack, D. H., and Davis, M. M. (1994). Blimp-1, a novel zinc finger-containing protein that can drive the maturation of B lymphocytes into immunoglobulin-secreting cells. *Cell* 77, 297-306.

Weinberg, R. A. (1995). The retinoblastoma protein and cell cycle control. *Cell* 81, 323-330.

Xie, M., Shao, G., Buyse, I.M., Huang, S. (1997). Transcriptional repression mediated by the PR domain zinc finger gene RIZ. *J. Biol. Chem.* in press.